AffyImmune Appoints Dr. Daniel Janse as Chief Executive Officer
NATICK, Mass. – AffyImmune, a clinical-stage biotechnology company committed to developing novel, first-in-class CAR T cell therapies, today announced the appointment of Daniel Janse, Ph.D. as President and Chief Executive Officer. Dr. Janse brings twenty years of expertise and an extensive background in biopharmaceutical research and development, operations, and leadership to drive the company forward. “We are thrilled to welcome Dr. Janse as the new … Continue reading AffyImmune Appoints Dr. Daniel Janse as Chief Executive Officer